GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Minerva Neurosciences
Minerva is a biotech company focused on CNS diseases. Its stock price reflects the long and arduous history of clinical trials for its lead drug. The chart is a classic biotech story of binary events, where the FDA's decision is everything.
Share prices of companies in the market segment - Neuro
Minerva Neurosciences is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, particularly schizophrenia. We've classified it under the "Neurology" umbrella. The chart below shows how investors assess risks in the psychiatry sector.
Broad Market Index - GURU.Markets
Minerva Neurosciences is a biotech company developing drugs to treat central nervous system disorders, such as schizophrenia. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Minerva shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
NERV - Daily change in the company's share price Minerva Neurosciences
Minerva Neurosciences, Inc.'s daily price change reflects the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials and FDA decisions regarding its drugs.
Daily change in the price of a set of shares in a market segment - Neuro
Minerva Neurosciences, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with NERV, which focuses on CNS diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Minerva Neurosciences is a biotech company specializing in the treatment of diseases of the central nervous system. Its shares are driven by news of clinical trials. This high volatility is a significant component of the overall "noise" and dynamics of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Minerva Neurosciences
Minerva Neurosciences' year-to-date performance is the story of its years-long battle for FDA approval of its schizophrenia drug. Its market capitalization over the past 12 months is fundamentally dependent on the regulator's decisions. The denial of approval was a serious blow, and now its valuation is determined by investors' faith in the company's ability to appeal the decision.
Annual dynamics of market capitalization of the market segment - Neuro
Minerva Neurosciences, Inc. is a late-stage biotech company developing drugs for the treatment of central nervous system disorders. Its stock price is entirely dependent on regulatory decisions by the FDA. The chart reflects the high risks and binary nature of the outcome for companies dependent on a single key product.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Minerva Neurosciences is a classic neurobiology company whose stock has followed the rhythm of clinical trials for years. Its performance relative to the market is a graph of the hopes and disappointments associated with the development of a key drug. Economic cycles play no role here; data and the FDA's verdict decide everything.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Minerva Neurosciences
Minerva is a biopharmaceutical company focused on CNS diseases. Its monthly performance is highly sensitive to regulatory decisions. FDA news regarding its lead drug for schizophrenia is the main driver of its volatility.
Monthly dynamics of market capitalization of the market segment - Neuro
Minerva Neurosciences is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders, such as schizophrenia. The chart below shows the overall dynamics in the neuroscience sector, which is one of the most challenging to develop drugs for, yet has a huge unmet need.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks, especially after trial failures, can move completely independently of the market. The chart below shows the overall sentiment. Is Minerva Neurosciences living up to its complex history, where only regulatory decisions matter?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Minerva Neurosciences
Minerva Neurosciences is a biopharmaceutical company specializing in diseases of the central nervous system. Its weekly stock price is extremely volatile, reflecting the long and arduous development of drugs for schizophrenia, as well as regulatory decisions.
Weekly dynamics of market capitalization of the market segment - Neuro
Minerva Neurosciences, a neuroscience company, is heavily dependent on research results. This chart allows us to isolate the unique investor reaction to the company's news from the overall sentiment in the biotech sector. Is the weekly price movement specific to Minerva?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Minerva Neurosciences is a biotech company whose stock moves in sync with clinical trial news. This chart is a great way to see how its weekly fluctuations are disconnected from overall market trends. Is the company living its own life, or is it being affected by the global sell-off?
Market capitalization of the company, segment and market as a whole
NERV - Market capitalization of the company Minerva Neurosciences
Minerva Neurosciences' market capitalization is a dramatic curve of hopes and disappointments in neuroscience. The chart clearly demonstrates how the company's valuation soared on expectations for a new schizophrenia drug and plummeted after setbacks in clinical trials and negotiations with the FDA.
NERV - Share of the company's market capitalization Minerva Neurosciences within the market segment - Neuro
Minerva Neurosciences is a biopharmaceutical company focused on treating diseases of the central nervous system. In the complex neuroscience segment, its market capitalization reflects the hopes and failures of new drug development. Fluctuations in this metric reflect regulatory decisions and clinical trial results, which are critical to the company's survival.
Market capitalization of the market segment - Neuro
Minerva Neurosciences is tackling brain diseases. How big is this arena? The chart below is a barometer of the neuroscience pharmaceutical sector. Its volatile dynamics reflect the enormous risks and potential rewards in finding cures for the most complex diseases, such as schizophrenia.
Market capitalization of all companies included in a broad market index - GURU.Markets
The chart for Minerva Neurosciences shows the dramatic story of a schizophrenia drug's development. Its market cap, which collapsed after clinical trial failures and regulatory issues, is a clear example of the binary risks in biotech. This diagram illustrates the high stakes involved in treating CNS diseases.
Book value capitalization of the company, segment and market as a whole
NERV - Book value capitalization of the company Minerva Neurosciences
For Minerva Neurosciences, a biopharmaceutical company, book value is its material basis, consisting primarily of financial reserves for conducting clinical trials of its CNS drugs. The chart below shows how this critical financial foundation has evolved.
NERV - Share of the company's book capitalization Minerva Neurosciences within the market segment - Neuro
Minerva Neurosciences is a biopharmaceutical company whose tangible assets are research laboratories focused on developing drugs for the treatment of central nervous system diseases. The chart shows the share of this specialized R&D infrastructure the company controls in its therapeutic niche.
Market segment balance sheet capitalization - Neuro
Minerva Neurosciences is a biotechnology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Minerva focuses on drug development, and its capital is its intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Minerva's book value is not its plants, but rather capital invested in clinical trials of drugs for the treatment of central nervous system disorders, particularly the negative symptoms of schizophrenia. These assets reflect the company's financial resources for working in this highly complex field of medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Minerva Neurosciences
Minerva Neurosciences is a biotech company developing drugs for the treatment of central nervous system disorders. Its market capitalization is highly volatile, reflecting the long history of the ups and downs of its lead drug. The chart is a story of hopes and disappointments related to the FDA's decision.
Market to book capitalization ratio in a market segment - Neuro
Minerva Neurosciences is a biotech company focused on diseases of the central nervous system. Its valuation is entirely dependent on clinical trial results and regulatory approval. The chart reflects investors' speculative expectations regarding its scientific developments.
Market to book capitalization ratio for the market as a whole
Minerva Neurosciences is a biopharmaceutical company focused on CNS diseases. Its entire value lies in its development pipeline and patents. This chart shows the extreme premium that investors are pricing in for successful clinical trials compared to companies with actual manufacturing assets.
Debts of the company, segment and market as a whole
NERV - Company debts Minerva Neurosciences
Minerva Neurosciences is a clinical-stage biotech company focused on diseases of the central nervous system. Developing drugs to treat such complex conditions takes decades and requires significant resources. This chart shows how the company raises funding to support its lengthy and expensive research and development programs.
Market segment debts - Neuro
Minerva Neurosciences is a late-stage biotech company focused on diseases of the central nervous system. After years of development and regulatory interactions, its financial future hinges on the approval of its lead drug. This chart shows its financial position at this critical juncture in its history.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Minerva Neurosciences
Minerva Neurosciences is a biotech company focused on CNS diseases. This chart shows its financial structure. For a company whose developments are in the late, but risky, stages of clinical trials, any debt is a significant burden. A research failure could make it impossible to service and threaten the company's survival.
Market segment debt to market segment book capitalization - Neuro
Minerva Neurosciences is a biopharmaceutical company focused on treating diseases of the central nervous system (CNS). Drug development in this area is extremely complex and risky. The chart shows the overall debt burden in the sector, providing context for assessing how the company finances its lengthy and expensive clinical programs.
Debt to book value of all companies in the market
Minerva Neurosciences is a biopharmaceutical company developing drugs for diseases of the central nervous system. After years of development and setbacks, it relies on investors' faith in its only drug candidate. This chart shows that debt financing is virtually unavailable to the company in such a risky situation.
P/E of the company, segment and market as a whole
P/E - Minerva Neurosciences
For Minerva Neurosciences, a company developing drugs for treating central nervous system disorders, the P/E ratio is not applicable. The company has no products on the market and no profit. Its valuation on this chart is arbitrary and does not reflect its true value, which depends entirely on the results of clinical trials.
P/E of the market segment - Neuro
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of central nervous system (CNS) disorders. This chart shows the average valuation for neuropharmaceuticals, providing investors with context for assessing the research pipeline and the risks associated with CNS drug development.
P/E of the market as a whole
Minerva Neurosciences is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. The company has experienced setbacks in clinical trials. Its valuation reflects not general market trends, but rather speculative hopes that it will ultimately secure approval for its lead drug despite these challenges.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Minerva Neurosciences
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on treating diseases of the central nervous system. This chart reflects investors' speculative expectations regarding the clinical trial results and the FDA's decision on its schizophrenia drug. The valuation is entirely dependent on future regulatory developments.
%20P%2FE%20Minerva%20Neurosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Minerva-Neurosciences&v=1772585866552 "Chart of the company's future (projected) P/E Minerva Neurosciences")
Future (projected) P/E of the market segment - Neuro
Minerva Neurosciences is a biopharmaceutical company focused on diseases of the central nervous system (CNS). Its valuation relative to other biotechs in this complex field reflects investor opinion on the chances of its drugs succeeding in clinical trials. This is an indicator of how the market assesses the risks and potential of its developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772585866562 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Minerva Neurosciences is a clinical-stage biotech focused on treating diseases of the central nervous system. Its shares are betting on the success of clinical trials. This chart shows the overall risk appetite of investors. For biotechs with a binary outcome (success or failure), market optimism is a significant driver of share price support.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772585866573 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Minerva Neurosciences
Minerva Neurosciences is a clinical-stage biotechnology company focused on treating diseases of the central nervous system. The financial performance presented here is almost entirely driven by R&D expenses. The company's future depends on the results of clinical trials and regulatory decisions regarding its drugs.
Profit of companies in the market segment - Neuro
Minerva Neurosciences is a biotech company focused on treating central nervous system disorders, such as schizophrenia. This chart reflects the financial health of the neuroscience segment of the biotech company, demonstrating how close this highly complex field of medicine is to developing commercially viable drugs.
Overall market profit
Minerva Neurosciences is a clinical-stage biotech company focused on diseases of the central nervous system. Its future, like that of many companies in the sector, depends solely on research results and drug approvals. The macroeconomic environment, reflected in this chart, has virtually no impact on NERV's scientific process.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Minerva Neurosciences
Minerva Neurosciences is a biotech company focused on treating diseases of the central nervous system. Its future profit forecast is entirely dependent on clinical trial results and regulatory approvals. This chart reflects analyst expectations for its lead drug candidate and its chances of reaching the market.
%20profit%20of%20the%20company%20Minerva%20Neurosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Minerva-Neurosciences&v=1772585866648 "Graph of future (projected) profit of the company Minerva Neurosciences")
Future (predicted) profit of companies in the market segment - Neuro
Minerva Neurosciences is a clinical-stage biopharmaceutical company specializing in the treatment of central nervous system disorders, particularly schizophrenia. This chart shows forecasts for the neuroscience segment. It illustrates the high risk and potential reward in an industry where success depends entirely on clinical trial results and regulatory approval.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772585866661 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
The investment climate illustrated by this chart is critical for biotech companies. Minerva Neurosciences, focused on CNS diseases, depends on an influx of capital for long-term and expensive research. A growing economy and risk appetite facilitate funding, while a recession hinders it.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772585866677 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Minerva Neurosciences
Minerva Neurosciences is a biotech company focused on CNS diseases. With minimal revenue, this metric reflects speculative expectations. It shows how much the market is willing to pay for the hope of successful approval of its drugs.
P/S market segment - Neuro
Minerva Neurosciences is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system (CNS) disorders. This chart shows the average valuation in the neuroscience sector. It reflects investor expectations for Minerva's developments and the risks associated with clinical trials of drugs for the treatment of complex mental disorders.
P/S of the market as a whole
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders, such as schizophrenia. Its valuation is a bet on future success in clinical trials. This chart highlights the difference between estimating potential and estimating actual market revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Minerva Neurosciences
Minerva Neurosciences is a biopharmaceutical company focused on treating diseases of the central nervous system. Its valuation is almost entirely dependent on clinical trial results. This chart shows investors' speculative bets that its drug candidates will be approved and generate significant future revenue.
%20P%2FS%20Minerva%20Neurosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Minerva-Neurosciences&v=1772585866732 "The graph of the company's future (projected) P/S Minerva Neurosciences")
Future (projected) P/S of the market segment - Neuro
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, particularly the negative symptoms of schizophrenia. This chart reflects investor expectations for its clinical trial results and future commercial success compared to other neuroscience companies.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772585866749 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
This chart reflects expectations for the biotech sector. For Minerva Neurosciences, a company developing drugs to treat central nervous system disorders, it's an indicator of investor risk appetite. Market optimism is essential for funding long and complex clinical trials in one of the most challenging areas of pharmaceuticals.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772585866756 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Minerva Neurosciences
Minerva Neurosciences is a biopharmaceutical company developing drugs for the treatment of central nervous system (CNS) disorders. This chart reflects revenue from collaborations. In the future, it will show revenue from sales of drugs for schizophrenia and other disorders, should they receive regulatory approval.
Sales of companies in the market segment - Neuro
Minerva Neurosciences is a biopharmaceutical company focused on treating central nervous system disorders, such as schizophrenia. This chart shows growth in the neuroscience sector. Developing drugs for the central nervous system is one of the most challenging areas in pharmaceuticals, and Minerva's efforts are part of a global search for breakthrough treatments.
Overall market sales
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on diseases of the central nervous system. Its market capitalization depends on research results. The overall economic situation, shown in this chart, sets the tone for the investment climate, influencing investors' willingness to finance long-term and risky projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Minerva Neurosciences
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders, particularly schizophrenia. Its future revenue is entirely dependent on the approval and commercial launch of its lead drug candidate. This chart reflects analysts' speculative expectations regarding the regulatory decision and the drug's potential.
%20sales%20of%20the%20company%20Minerva%20Neurosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Minerva-Neurosciences&v=1772585866829 "Schedule of future (projected) sales of the company Minerva Neurosciences")
Future (projected) sales of companies in the market segment - Neuro
Minerva Neurosciences is a biopharmaceutical company developing drugs to treat diseases of the central nervous system. This chart reflects expectations for the entire neuroscience sector. It shows the potential analysts see in this complex field, where the need for new treatments remains enormous.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772585866857 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on treating diseases of the central nervous system. Its valuation depends on the results of clinical trials. The overall economic situation, shown in this chart, affects the availability of capital for biotech companies to conduct expensive neuroscience research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772585866864 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Minerva Neurosciences
Minerva Neurosciences is a biotech company focused on treating diseases of the central nervous system. The chart illustrates financial results in late-stage clinical trials. Profitability is currently negative, as the company is incurring significant expenses seeking regulatory approval for its key drug.
Market segment marginality - Neuro
Minerva Neurosciences is a biotech company focused on diseases of the central nervous system. For a company conducting clinical trials, this chart provides a benchmark. It reflects the average profitability of successful companies in the sector, illustrating the financial potential that could be realized if their drugs are approved.
Market marginality as a whole
Minerva Neurosciences is a biopharmaceutical company developing drugs for the treatment of diseases of the central nervous system. This overall market profitability chart is irrelevant to the company. The company's future depends solely on the results of clinical trials and regulatory decisions. Its success or failure is determined by science, not economic cycles.
Employees in the company, segment and market as a whole
Number of employees in the company Minerva Neurosciences
Minerva Neurosciences is a biopharmaceutical company focused on diseases of the central nervous system. This graph shows a very small team, typical for a company in late-stage clinical development, where most of the work is conducted with contract research organizations.
Share of the company's employees Minerva Neurosciences within the market segment - Neuro
Minerva Neurosciences is focused on treating diseases of the central nervous system, one of the most complex areas of medicine. This chart shows the percentage of leading neuroscientists, psychiatrists, and clinicians the company attracts. It reflects its concentration of unique scientific talent in developing drugs for severe brain disorders.
Number of employees in the market segment - Neuro
Minerva Neurosciences is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders, such as schizophrenia. This is one of the most complex areas in medicine. This graph illustrates how research-intensive modern neuroscience is, requiring the involvement of top neuroscientists and psychiatrists.
Number of employees in the market as a whole
Minerva Neurosciences works to treat brain diseases, which requires long-term investment in science. This graph reflects the current state of the labor market, but its future is being shaped in the labs of these companies. Their work creates unique jobs for neurobiologists and chemists, advancing one of the most complex fields of medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Minerva Neurosciences (NERV)
Minerva Neurosciences is a biotech company focused on CNS diseases. This chart represents a pure intellectual capital valuation. The company has no mass sales; its value is based entirely on market expectations for its drug candidates. The chart shows this high potential value embedded in IP and clinical research, per scientist.
%20of%20the%20company%20Minerva%20Neurosciences%20(NERV)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Minerva-Neurosciences-NERV&v=1772585866967 "Chart of market capitalization per employee (in thousands of dollars) of the company Minerva Neurosciences (NERV)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Minerva Neurosciences develops drugs to treat diseases of the central nervous system. This is a field with long research cycles and high risks. The capitalization per employee here represents the investors' bet on the team's scientific potential. The chart compares this "bet" with other neuroscience companies, assessing the uniqueness of their developments.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772585867011 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Minerva Neurosciences is a biopharmaceutical company focused on treating diseases of the central nervous system. This chart shows the average market value generated by one specialist, highlighting the high scientific potential in this complex medical field.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772585867071 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Minerva Neurosciences (NERV)
Minerva Neurosciences is a clinical-stage biotech company focused on CNS diseases. The company has no commercial products. This chart shows the net loss per employee. It reflects how much the company invests in each scientist to conduct complex and expensive brain research.
%20Chart%20Minerva%20Neurosciences%20(NERV)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Minerva-Neurosciences-NERV&v=1772585867109 "Company Profit Per Employee (in thousands of dollars) Chart Minerva Neurosciences (NERV)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Minerva Neurosciences is a biopharmaceutical company focused on developing treatments for diseases of the central nervous system. The business requires significant investment in long-term clinical trials involving a team of scientists. This chart allows you to assess how the company manages its intellectual capital and reflects the potential future value of its developments per employee.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772585867123 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Minerva Neurosciences (NERV) is a clinical-stage biotech company focused on developing drugs for the treatment of central nervous system (CNS) disorders, particularly schizophrenia. This is an R&D business. This chart shows the average profitability per employee across the market. For NERV (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772585867168 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Minerva Neurosciences (NERV)
Minerva Neurosciences is a clinical-stage biopharmaceutical company working on the treatment of central nervous system disorders. For such a company, this chart is a sign of hope. It reflects enormous future potential if its drugs pass trials and are approved, leading to explosive revenue growth.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Minerva-Neurosciences-NERV&v=1772585867276 "Sales chart per company employee Minerva Neurosciences (NERV)")
Sales per employee in the market segment - Neuro
Minerva Neurosciences is a clinical-stage biotech company focused on treating CNS disorders. Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of Minerva's staff within the industry.
Sales per employee for the market as a whole
Minerva Neurosciences is a clinical-stage biotechnology company focused on diseases of the central nervous system. The company has no approved products and, therefore, no commercial revenue. This metric is irrelevant, as the entire value of a scientific team lies in their R&D potential, not current sales.
Short shares by company, segment and market as a whole
Shares shorted by company Minerva Neurosciences (NERV)
Minerva Neurosciences is a biotech company that spent years developing a drug (Roluperidone) to treat the negative symptoms of schizophrenia. The FDA has already rejected the company's approval. This chart shows investors' bets that the drug will never be approved. The bears believe the trial data is inconclusive and the company is heading for bankruptcy.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Minerva-Neurosciences-NERV&v=1772585867395 "Short Shares Chart for the Company Minerva Neurosciences (NERV)")
Shares shorted by market segment - Neuro
Minerva Neurosciences is a biotech company focused on treating central nervous system disorders, particularly the negative symptoms of schizophrenia. This is one of the most complex areas in medicine. This chart shows the overall short position in the neuroscience-focused biotech sector. Its rise reflects extreme investor skepticism regarding the success of clinical trials in this challenging area.
Shares shorted by the overall market
Minerva Neurosciences is a biotech company that suffered a major R&D setback (for a schizophrenia drug). This chart illustrates the overall market pessimism. When investors are fearful, they are completely intolerant of companies with a history of failure. The market doesn't believe in second chances and sells off shares, expecting nothing but bankruptcy.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Minerva Neurosciences (NERV)
This oscillator for Minerva Neurosciences is a story of "last resort" in psychiatry. The company has been trying to secure FDA approval for its schizophrenia drug for years. "Overheating" (above 70) occurs on any rumors of possible approval. A firm FDA rejection due to questionable trial data keeps the stock deeply "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Minerva-Neurosciences-NERV&v=1772585867616 "RSI 14 indicator chart for the company's stock Minerva Neurosciences (NERV)")
RSI 14 Market Segment - Neuro
Minerva (NERV) is a "biotech" stock, a "schizophrenia hunter." The "Neuro" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is NERV's growth due to its R&D, or is the entire biotech sector simply overheated by expectations?
RSI 14 for the overall market
Minerva Neurosciences (NERV) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NERV (Minerva Neurosciences)
Minerva Neurosciences (NERV) is a biotech company focused on treating central nervous system disorders, particularly the negative symptoms of schizophrenia. This chart shows the average target price. It reflects the extremely challenging analyst assessment of the regulatory prospects for its lead drug.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NERV-Minerva-Neurosciences&v=1772585867714 "A chart showing analyst consensus forecasts for the expected stock price. NERV (Minerva Neurosciences)")
The difference between the consensus estimate and the actual stock price NERV (Minerva Neurosciences)
Minerva Neurosciences is a biotech company focused on developing drugs to treat severe CNS disorders, particularly the negative symptoms of schizophrenia. This chart shows analysts' forecasts for the stock's upside and downside potential. It measures the gap between the price and forecast, reflecting their view of the company's risky R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NERV-Minerva-Neurosciences&v=1772585867741 "A chart showing the difference between the consensus forecast and the actual stock price. NERV (Minerva Neurosciences)")
Analyst consensus forecast for stock prices by market segment - Neuro
Minerva is a biotech focused on treating schizophrenia. The company spent years developing its lead drug, seeking FDA approval. This chart reflects analysts' overall expectations across the neuroscience sector, demonstrating whether experts believe breakthroughs in the treatment of complex CNS disorders are possible.
Analysts' consensus forecast for the overall market share price
Minerva Neurosciences is a biotech company specializing in developing drugs for the treatment of central nervous system disorders, particularly schizophrenia. This chart shows the overall market "risk appetite." For Minerva, a company with a history of regulatory setbacks, overall market optimism (the rising chart) is critical for raising capital for new efforts.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Minerva Neurosciences
Minerva Neurosciences is a biotech company whose fate (and downfall) is tied to a single drug (Roluperidone) for schizophrenia, which failed key studies but which they are still trying to push through the FDA. This chart is a summary of their battle with the FDA. It reflects their (nearly zero) chances of approval, their cash burn, and their desperate struggle.
AKIMA Market Segment Index - Neuro
Minerva Neurosciences (NERV) is a biopharmaceutical company specializing in CNS diseases. Their primary focus is reluperidone for the treatment of negative symptoms of schizophrenia. The chart shows the segment average index, helping investors assess how NERV's risks in this complex area compare to the average.
The AKIM Index for the overall market
Minerva Neurosciences is a biopharmaceutical company focused on treating the negative symptoms of schizophrenia (Roluperidone). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is overcoming regulatory hurdles, compares to overall economic trends.
